In a nutshell This study examined the benefits of nanoparticle albumin-bound paclitaxel in combination with bevacizumab as first-line treatment (the first treatment of choice) for metastatic breast cancer patients. Some background Paclitaxel is one of several chemotherapy drugs used to treat cancer. However, treatment is often associated with...
Read More
A total of 173 patients with metastatic (a cancer that has spread to other organs) TNBC were involved in the study. 115 patients were assigned to receive cisplatin and cetuximab together, while 58 patients received cisplatin alone. 20% of the patients treated with cisplatin plus cetuximab showed some response to treatment, compared to only...
Read More
In a nutshell This phase 3 clinical trial compared the safety and efficacy of two different combination treatments in women with early stage breast cancer: anastrozole (Arimidex) plus goserelin (Zoladex) versus tamoxifen (Nolvadex) plus goserelin. Some background An estrogen-receptor positive (ER+) breast cancer requires estrogen (the primary...
Read More
In a nutshell This laboratory based study investigates the use of compounds which block TGF-β signalling in triple negative breast cancer cells. They show that inhibiting this process prevents the development of paclitaxel resistance and the recurrence of cancers following paclitaxel treatment. Some background Triple negative...
Read More
In a nutshell This paper looks at the use of a system called EPclin that gives patients a risk score according to the clinical and genetic characteristics of their tumor. This score is used to predict if patients are at high or low risk of distant reccurrence of the tumor and if they would benefit from chemotherapy. Some background...
Read More
This paper reviews chemotherapy options for triple-negative breast cancers. Breast cancer cells express 3 main receptors that can be targeted with therapy: Estrogen receptors (ER), Progesterone receptors (PR) and HER2. Triple-negative breast cancers (TNBCs) do not express these 3 receptors and make up approximately 15% of breast cancers. Such tumors do...
Read More
